Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lincheng Fang

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
ACS Medicinal Chemistry Letters|November 20, 2020
Identification of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors for the Treatment of Colorectal CancerYifei Yang, Lincheng Fang, Pan Chen, et al.
Immunopharmacology and Immunotoxicology|February 23, 2021
Insight into the dichotomous regulation of STING activation in immunotherapyZhaoxue Hu, Yifei Yang, Lincheng Fang, et al.
JACS Au|July 26, 2024
Modular Development of Enzyme-Activatable Proteolysis Targeting Chimeras for Selective Protein Degradation and Cancer TargetingYanchi Chen, Lina Zhang, Lincheng Fang, et al.
Bioorganic & Medicinal Chemistry|April 16, 2021
Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) familyLincheng Fang, Zhaoxue Hu, Yifei Yang, et al.
Bioorganic & Medicinal Chemistry|September 4, 2021
Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interactionLincheng Fang, Jiping Tian, Kaixuan Zhang, et al.
European Journal of Medicinal Chemistry|February 15, 2024
Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospectsDezhong Guan, Lincheng Fang, Mingshun Feng, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
ACS Medicinal Chemistry Letters|November 20, 2020
Identification of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors for the Treatment of Colorectal CancerYifei Yang, Lincheng Fang, Pan Chen, et al.
Immunopharmacology and Immunotoxicology|February 23, 2021
Insight into the dichotomous regulation of STING activation in immunotherapyZhaoxue Hu, Yifei Yang, Lincheng Fang, et al.
JACS Au|July 26, 2024
Modular Development of Enzyme-Activatable Proteolysis Targeting Chimeras for Selective Protein Degradation and Cancer TargetingYanchi Chen, Lina Zhang, Lincheng Fang, et al.
Bioorganic & Medicinal Chemistry|April 16, 2021
Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) familyLincheng Fang, Zhaoxue Hu, Yifei Yang, et al.
Bioorganic & Medicinal Chemistry|September 4, 2021
Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interactionLincheng Fang, Jiping Tian, Kaixuan Zhang, et al.
European Journal of Medicinal Chemistry|February 15, 2024
Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospectsDezhong Guan, Lincheng Fang, Mingshun Feng, et al.
Pageof 1